From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Structural formula of lisinopril
Ball-and-stick model of the lisinopril zwitterion
Chemical structure of lisinopril
Clinical data
Pronunciation/lˈsɪnəprɪl/, ly-SIN-ə-pril
Trade namesPrinivil, Zestril, others[2]
Synonyms(2S)-1-[(2S)-6-amino-2-{[(1S)-1-carboxy-3-phenylpropyl]amino}hexanoyl]pyrrolidine-2-carboxylic acid
  • D (not recommended)[1]
Routes of
By mouth
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailabilityapprox. 25%, but wide range between individuals (6 to 60%)
Protein binding0
Elimination half-life12 hours
ExcretionEliminated unchanged in urine
CAS Number
PubChem CID
PDB ligand
ECHA InfoCard100.071.332 Edit this at Wikidata
Chemical and physical data
Molar mass405.488 g/mol
3D model (JSmol)
 ‹See TfM›☒N☑Y (what is this?)  (verify)

Lisinopril is a drug of the angiotensin-converting enzyme (ACE) inhibitor class used primarily in treatment of high blood pressure, heart failure, and after heart attacks. It is also used for preventing kidney and eye complications in people with diabetes. Its indications, contraindications, and side effects are as those for all ACE inhibitors.

Lisinopril was the third ACE inhibitor (after captopril and enalapril) and was introduced into therapy in the early 1990s.[3] A number of properties distinguish it from other ACE inhibitors: It is hydrophilic, has a long half-life and tissue penetration, and is not metabolized by the liver.

Medical uses[edit]

Lisinopril is typically used for the treatment of high blood pressure, congestive heart failure, acute myocardial infarction (heart attack), and diabetic nephropathy.[4]

A systematic review concluded that lisinopril was highly effective for treatment of proteinuric kidney disease, including diabetic proteinuria.[5]

Specific populations[edit]

Caution should be used in the following populations, as dose adjustments may be required.

Kidney problems[edit]

The dose must be adjusted in those with poor kidney function. Dose adjustments may be required when creatinine clearance is less than or equal to 30mL/min. Since lisinopril is removed by dialysis, dosing changes must also be considered for people on dialysis.[1]

Pregnancy and breastfeeding[edit]

Lisinopril has been assigned to pregnancy category D by the FDA. Animal and human data have revealed evidence of lethal harm to the embryo and teratogenicity associated with ACE inhibitors. No controlled data in human pregnancy are available. Birth defects have been associated with use of lisinopril in any trimester. However, there have been reports of death and increased toxicities to the fetus and newly born child with the use of lisinopril in the second and third trimesters. The label states, "When pregnancy is detected, discontinue Zestril as soon as possible." The manufacturer recommends mothers should not breastfeed while taking this medication because of the lack of safety data that currently exists.[1]


Treatment with lisinopril should be avoided for people who have a history of angioedema (hereditary or idiopathic) or who have diabetes and are taking aliskiren.[1]

Adverse effects[edit]

The incidence of adverse effects varies according to which disease state the patient is being treated for.[1]

People taking lisinopril for the treatment of hypertension may experience the following side effects:

  • Headache (3.8%)
  • Dizziness (3.5%)
  • Cough (2.5%)
  • Difficulty swallowing or breathing (signs of angioedema), allergic reaction (anaphylaxis)
  • Hyperkalemia (2.2% in adult clinical trials)
  • Fatigue (1% or more)
  • Diarrhea (1% or more)
  • Some severe skin reactions have been reported rarely, including toxic epidermal necrolysis and Stevens-Johnson syndrome; causal relationship has not been established.

People taking lisinopril for the treatment of myocardial infarction may experience the following side effects:

People taking lisinopril for the treatment of heart failure may experience the following side effects:

Lisinopril 40-mg oral tablet


In one reported overdose, the half-life of lisinopril was prolonged to 14.9 hours.[6] The case report of the event estimates that the individual consumed between 420 and 500 mg of lisinopril and survived.[7] In cases of overdosage, it can be removed from circulation by dialysis.[1]


Dental care[edit]

ACE-inhibitors like lisinopril are considered to be generally safe for people undergoing routine dental care, though the use of lisinopril prior to dental surgery is more controversial, with some dentists recommending discontinuation the morning of the procedure.[8] People may present to dental care suspicious of an infected tooth, but the swelling around the mouth may be due to lisinopril-induced angioedema, prompting emergency, medical referral.[8]


Lisinopril is the lysine-analog of enalapril. Unlike other ACE inhibitors, it is not a prodrug and is excreted unchanged in the urine.[1]

Mechanism of action[edit]

Lisinopril is an ACE inhibitor, meaning it blocks the actions of angiotensin-converting enzyme (ACE) in the renin-angiotensin-aldosterone system (RAAS), keeping angiotensin I from being converted to angiotensin II. This prevents the release of aldosterone from the adrenal cortex, which allows the kidney to excrete sodium along with water into the urine, and retention of potassium ions.[9] Specifically, this process occurs in the peritubular capillaries of the kidneys in response to a change in Starling forces.[10] The inhibition of the RAAS system causes an overall decrease in blood pressure.[9]



Lisinopril has a poor bioavailability of 25% (reduced to 16% in people with NYHA Class II-IV heart failure).[1][9] Its time to peak concentration is 7 hours.[1][9] The peak effect of lisinopril is about 4 to 8 hours after administration.[11] Food does not affect its absorption.[11]


Lisinopril does not bind to proteins in the blood.[1][9] It does not distribute as well in people with NYHA Class II–IV heart failure.[1][9]


Lisinopril is the only water-soluble member of the ACE inhibitor class, with no hepatic metabolism.[11]


Lisinopril leaves the body completely unchanged in the urine.[1][9] The half-life of lisinopril is 12 hours, and is increased in people with kidney problems.[1][9] While the plasma half-life of lisinopril has been estimated between 12–13 hours, the elimination half-life is much longer, at around 30 hours.[11] The full duration of action is between 24 and 30 hours.[11]


Pure lisinopril powder is white to off-white in color.[1] Lisinopril is soluble in water (approximately 13 mg/L at room temperature),[12] less soluble in methanol, and virtually insoluble in ethanol.[1]


Captopril, the first ACE inhibitor, is a functional and structural analog of a peptide derived from the venom of the jararaca, a Brazilian pit viper (Bothrops jararaca).[13] Enalapril is a derivative, designed by scientists at Merck to overcome the rash and bad taste caused by captopril.[14][15]:12–13 Enalapril is actually a prodrug; the active metabolite is enalaprilat.[16]

Lisinopril is a synthetic peptide derivative of captopril.[17] Scientists at Merck created lisinopril by systematically altering each structural unit of enalaprilat, substituting various amino acids. Adding lysine at one end of the drug turned out to have strong activity and was orally available; analogs of that compound resulted in lisinopril, which takes its name from the discovery with lysine. Merck conducted clinical trials, and the drug was approved for hypertension in 1987 and congestive heart failure in 1993.[16]

The discovery posed a problem, since sales of enalapril were strong for Merck, and the company did not want to diminish those sales. Merck ended up entering into an agreement with Zeneca under which Zeneca received the right to co-market lisinopril, and Merck received the exclusive rights to an earlier stage aldose reductase inhibitor drug candidate, a potential treatment for diabetes. Zeneca's marketing and brand name, "Zestril", turned out to be stronger than Merck's effort.[18] The drug became a blockbuster for Astrazeneca (formed in 1998), with annual sales in 1999 of $1.2B.[19]

The US patents expired in 2002.[19] Since then, lisinopril has been available under many brand names worldwide; some formulations include the diuretic hydrochlorothiazide.[2]


  1. ^ a b c d e f g h i j k l m n o Lisinopril label Revised: 08/2015
  2. ^ a b International brands and formulations for lisinopril Page accessed April 23, 2016
  3. ^ Patchett A; et al. (1980). "A new class of angiotensin-converting enzyme inhibitors". Nature. 288 (5788): 280–3. Bibcode:1980Natur.288..280P. doi:10.1038/288280a0. PMID 6253826.
  4. ^ "Lisinopril". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
  5. ^ Sadat-Ebrahimi SR, Parnianfard N, Vahed N, Babaei H, Ghojazadeh M, Tang S, Azarpazhooh A (July 2018). "An evidence-based systematic review of the off-label uses of lisinopril". Br J Clin Pharmacol. doi:10.1111/bcp.13705. PMID 29971804.
  6. ^ "HSDB: LISINOPRIL". U.S. National Library of Medicine. Retrieved 6 June 2018.
  7. ^ Dawson, AH; Harvey, D; Smith, AJ; Taylor, M; Whyte, IM; Johnson, CI; Cubela, RB; Roberts, MJ (24 February 1990). "Lisinopril overdose". Lancet. 335 (8687): 487–8. PMID 1968218.
  8. ^ a b Weinstock, Robert; Johnson, Michael (2016). "Review of Top 10 Prescribed Drugs and Their Interaction with Dental Treatment". Dental Clinics of North America. 60 (2): 421–434.
  9. ^ a b c d e f g h Katzung, Bertram (2012). Basic and Clinical Pharmacology. New York City, New York: McGraw Hill. pp. 175, 184–85. ISBN 978-0-07-176401-8.
  10. ^ Reddi, Alluru (2018). "Disorders of ECF Volume: Nephrotic Syndrome". Fluid, Electrolyte and Acid-Base Disorders. Springer. ISBN 978-3-319-60167-0.
  11. ^ a b c d e Khan, M. Gabriel (2015). "Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers". Cardiac Drug Therapy. New York: Springer. ISBN 978-1-61779-962-4.
  12. ^ "Lisinopril". National Center for Biotechnology Information. Retrieved 6 June 2018.
  13. ^ Patlak M (March 2004). "From viper's venom to drug design: treating hypertension". FASEB J. 18 (3): 421. doi:10.1096/fj.03-1398bkt. PMID 15003987.
  14. ^ Jenny Bryan for The Pharmaceutical Journal, 17 Apr 2009 "From snake venom to ACE inhibitor—the discovery and rise of captopril"
  15. ^ Jie Jack Li, "History of Drug Discovery". Chapter 1 in Drug Discovery: Practices, Processes, and Perspectives. Eds. Jie Jack Li, E. J. Corey. John Wiley & Sons, Apr 3, 2013 ISBN 9781118354469
  16. ^ a b Menard J and Patchett A. "Angiotensin-Converting Enzyme Inhibitors". pp. 14–76 in Drug Discovery and Design. Volume 56 of Advances in Protein Chemistry. Eds. Richards FM, Eisenberg DS, and Kim PS. Series Ed. Scolnick EM. Academic Press, 2001. ISBN 9780080493381. pp. 30–33
  17. ^
  18. ^ David R. Glover. Vie D’or: Memoirs of a Pharmaceutical Physician. Troubador Publishing Ltd, 2016. ISBN 9781785894947. Merck Sharp and Dohme: lisinopril section
  19. ^ a b Express Scripts. Patent expirations

Further reading[edit]

External links[edit]